Cellular immunotherapy in multiple myeloma

In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendri...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of internal medicine Vol. 34; no. 5; pp. 954 - 965
Main Authors Vo, Manh-Cuong, Lakshmi, Thangaraj Jaya, Jung, Sung-Hoon, Cho, Duck, Park, Hye-Seong, Chu, Tan-Huy, Lee, Hyun-Ju, Kim, Hyeoung-Joon, Kim, Sang-Ki, Lee, Je-Jung
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Association of Internal Medicine 01.09.2019
대한내과학회
Subjects
Animals
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Cancer Vaccines - adverse effects
Cancer Vaccines - therapeutic use
cellular immunotherapy
dendritic cells
Dendritic Cells - immunology
Dendritic Cells - transplantation
engineered effector t cell
Humans
immunomodulatory drug
Immunotherapy, Adoptive - adverse effects
killer cells, natural
Killer Cells, Natural - immunology
Killer Cells, Natural - transplantation
multiple myeloma
Multiple Myeloma - genetics
Multiple Myeloma - immunology
Multiple Myeloma - pathology
Multiple Myeloma - therapy
Receptors, Chimeric Antigen - genetics
Receptors, Chimeric Antigen - immunology
Review
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Treatment Outcome
내과학
Killer cells, natural
Cellular immunotherapy
Dendritic cells
Engineered effector T cell
Immunomodulatory drug
Multiple myeloma
Online AccessGet full text
ISSN1226-3303
2005-6648
2005-6648
DOI10.3904/kjim.2018.325

Cover

More Information
Summary:In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ISSN:1226-3303
2005-6648
2005-6648
DOI:10.3904/kjim.2018.325